Skip to main content

Advertisement

SpringerLink
Log in

Predictors and survival in patients with melanoma brain metastases

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Brain metastases (BM) are one of the most frequent neurological complications of cancers. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10–40 %, and many patients have subclinical BM (>73 %). We computer-searched the clinical records of all our patients registered into a database to identify patients that presented or developed BM. A total of 49 patients with melanoma BM were included in our analysis. General time to brain metastases (TTBM) was 23 months. The nonparametric test between TTBM and the single variables showed an association between TTBM and Breslow thickness (p < 0.0076; Spearman’s coefficient—0.411), ulceration (p = 0.0656; Spearman’s coefficient—0.287) and positive sentinel lymph node (p < 0.0015; Spearman’s coefficient—0.475). Performing multiple regression, positive SLN remained the only, statistically significant, predictive variable (p < 0.01). Regarding the first melanoma site, the axial sites were more likely to develop BM than peripheral ones (p < 0.001). The analysis of brain metastasis survival (BMS) with Kaplan–Meier curves has resulted in a median survival rate of 6 months (range 1–134 months) and was strongly related to response to treatment, number of parenchymal lesions, presence or absence of symptoms. The results of the current analysis revealed clinical and primary tumor characteristics associated with the development of BM, TTBM, and BMS. The SNL was found to be the strongest predictor for BM development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Nayak L, Quant Lee E, Wen PY. Epidemiology of brain metastases. Cur Oncol Rep. 2012;14:48–54.

    Article  Google Scholar 

  2. De Angelis LM, Posner JB. Neurologic complications of cancer. New York: Oxford University Press; 2009.

    Google Scholar 

  3. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973–2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–72.

    Article  PubMed  Google Scholar 

  4. Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, et al. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res. 2011;30:10.

    Article  PubMed  Google Scholar 

  5. Counsell CE, Collie DA, Grant R. Incidence of intracranial tumors in the Lothian region of Scotland, 1989–1990. J Neurol Neurosurg Psychiatry. 1996;61:143–50.

    Article  PubMed  CAS  Google Scholar 

  6. Flanigan JC, Jilaveanu LB, Faries M, Sznol M, Ariyan S, Yu JB, et al. Melanoma brain metastases: is it time to reassess the bias? Curr Probl Cancer. 2011;35:200–10.

    Article  PubMed  Google Scholar 

  7. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135:807–10.

    Article  PubMed  CAS  Google Scholar 

  8. de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983;43:3427–33.

    PubMed  Google Scholar 

  9. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11–20.

    Article  PubMed  CAS  Google Scholar 

  10. Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 2011;117:1711–20.

    Article  PubMed  Google Scholar 

  11. Trinh VA, Hwu W-J. Chemoprevention for brain metastases. Curr Oncol Rep. 2012;14:63–9.

    Article  PubMed  CAS  Google Scholar 

  12. Meier S, Baumer BG, Maier T, Wellis G, Burg G, Seifert B, et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie. 2004;27:145–9.

    Article  PubMed  CAS  Google Scholar 

  13. Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomeigeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuros Oncol. 2008;10:199–207.

    Article  Google Scholar 

  14. Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0–4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Onco 2000;l7:87–7.

    Google Scholar 

  15. Eigenther TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, et al. Number of metastases, serum lactate deydrogenase level, and type of treatment and prognostic factors in patients with brain metasatses of malignant melanoma. Cancer. 2011;117:1697–703.

    Article  Google Scholar 

  16. Grob JJ, Regis J, Laurans R, Delaunay M, Wolkenstein P, Paul K, et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de cancerologie Cutanee. Eur J Cancer. 1998;10:1187–92.

    Article  Google Scholar 

  17. Raizer JJ, Hwu WJ, Pangeas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomenigeal metastases from cutanous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008;10:199–207.

    Article  PubMed  Google Scholar 

  18. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117:1687–96.

    Article  PubMed  Google Scholar 

  19. Retsas S, Gershuny AR. Central nervous system involvement in malignant melanoma. Cancer. 1988;61:1926–34.

    Article  PubMed  CAS  Google Scholar 

  20. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer. 2010;102:1213–8.

    Article  PubMed  CAS  Google Scholar 

  21. Boogerd W, de Gast GC, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer. 2007;109:306–12.

    Article  PubMed  CAS  Google Scholar 

  22. Schild SE, Behl D, Markovic SN, Brown PD, Sande JR, Deming RL, et al. Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy? Am J Clin Oncol. 2010;33:633–6.

    Article  PubMed  CAS  Google Scholar 

  23. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293.

    Article  PubMed  CAS  Google Scholar 

  24. Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH. Survival by Radiation Therapy Oncology Group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer. 2002;94:2265–72.

    Article  PubMed  Google Scholar 

  25. Harrison BE, Johnson JL, Clough RW, Halperin EC. Selection of patients with melanoma brain metastases for aggressive treatment. Am J Clin Oncol. 2003;26:354–7.

    PubMed  Google Scholar 

  26. Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer. 1984;53:2550–2.

    Article  PubMed  CAS  Google Scholar 

  27. Le Scodan R, Jouanneau L, Massard C, Gutierrez M, Kirova Y, Cherel P, et al. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. Cancer. 2011;11:395.

    PubMed  Google Scholar 

  28. Zacest AC, Besser M, Stevens G, Thompson JF, McCarthy WH, Culjak G. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg. 2002;96:552.

    Article  PubMed  Google Scholar 

  29. Kaye AH, Lawws ER Jr. Brain tumors. An encyclopedic approach. New York: Churchill Livingstone; 1995.

    Google Scholar 

  30. Ewend MG, Carey LA, Brem H. Treatment of melanoma metastases in the brain. Semin Surg Oncol. 1996;12:429.

    Article  PubMed  CAS  Google Scholar 

  31. Wronski M, Arbit E. Surgical treatment of brain metatsases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93:9–18.

    Article  PubMed  CAS  Google Scholar 

  32. Goldlust SA, Hsu M, Lassman AB, Panageas KS, Avila EK. Seizure prophylaxis and melanoma brain metastases. J Neuroncol. 2012;108:109–14.

    Article  CAS  Google Scholar 

  33. Goulart RC, Mattei TA, Ramina R. Cerebral melanoma metastases: a critical review on diagnosis methods and therapeutic options. ISNR Surg 276908 (2011).

  34. Bottoni U, Bonaccorsi P, Devirgiliis V, Panasiti V, Borroni RG, Trasimeni G, et al. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. Jpn J Clin Oncol. 2005;35:507–13.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. University Magna Graecia, V.le Europa, 88100, Catanzaro, Italy

    Ugo Bottoni

  2. Clinica Dermatologica, Dipartimento di Medicina Interna e Specialità Mediche, University of Rome, La Sapienza, Viale del Policlinico, Rome, Italy

    Rita Clerico, Giovanni Paolino, Marina Ambrifi, Paola Corsetti & Stefano Calvieri

Authors
  1. Ugo Bottoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rita Clerico
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giovanni Paolino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marina Ambrifi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paola Corsetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stefano Calvieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ugo Bottoni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bottoni, U., Clerico, R., Paolino, G. et al. Predictors and survival in patients with melanoma brain metastases. Med Oncol 30, 466 (2013). https://doi.org/10.1007/s12032-013-0466-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0466-2

Keywords

Search

Navigation